Published: Jun, 2018

The global cancer immunotherapy market is predicted in a publication by Transparency Market Research (TMR) to hold a fragmented characteristic because of the presence of several small and large companies. According to a finding of the publication, the market has witnessed the lead secured by Roche Holding AG in the recent years. The company’s stronger position obtained in the market could be a result of the approval of Avastin, Rituxan, and other monoclonal antibody drugs. Showing their prominence in monoclonal antibody and immune checkpoint inhibitor domains, Novartis, Merck, and Bristol-Myers Squibb are some of the other leading players of the market.

Between 2016 and 2024, TMR prognosticates the global cancer immunotherapy market to rise at a 14.6% CAGR to achieve a valuation of US$124.88 bn by the completion of 2024. On the basis of type of therapy, monoclonal antibodies could make it to a top position of the market, taking into account their US$29.0 bn valuation attained in 2016. By region, Europe and North America are foreseen to bag larger shares of the market.

cancer immunotherapy market

Growing Adoption of Immunotherapy over Traditional Therapeutics to Augur Well

The world cancer immunotherapy market is foretold to gain impetus due to rising popularity of patient assistance programs and broad portfolio of promising pipeline drugs. However, there could be more significant factors augmenting the demand in the market. For instance, rise in requirement of cancer monoclonal antibodies and launch of more effective bioinformatics tools offering improved drug development options could help with more demand for cancer immunotherapy. Furthermore, surge in adoption of immunotherapy therapeutics compared to conventional ones and high incidence of cancer could help the market to increase growth in the coming years.

In the U.S., Opdivo (nivolumab) and Keytruda (pembrolizumab) have been approved by the FDA. Product approvals could be another positive factor working in the favor of the world cancer immunotherapy market.

High Cost of Development of Novel Drugs to Pose Strong Challenge to Manufacturers

The international cancer immunotherapy market is forecasted to drop signs of promising growth for the next few years. However, certain factors have been analyzed by the authors of the TMR publication to raise fears of dwindling demand in the market. These include stringent government regulations, risk of side effects, and expensive development cost of new drugs. On the other hand, patent expiry of top drugs and poor infrastructure for cancer screening and diagnosis in developing nations are envisaged to trouble growth in the foreseeable future.

Nonetheless, advent of combination and targeted therapies and biosimilars could create ample of opportunities in the international cancer immunotherapy market. Rapid penetration of social media resulting into high awareness about cancer in urban areas is expected to help the market to achieve the limelight.

The information presented in this review is based on a TMR report, titled “Cancer Immunotherapy Market (Therapy - Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines; Therapeutic Area - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancer; End User - Hospitals, ASCs, Cancer Research Institutes, and Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

The global cancer immunotherapy market has been segmented as presented below:

Global Cancer Immunotherapy Market: Therapy

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
    • PD-1/PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines

Global Cancer Immunotherapy Market: Therapeutic Area

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancers

Global Cancer Immunotherapy Market: End User

  • Hospitals
  • ASCs
  • Cancer Research Centers
  • Clinics

 Global Cancer Immunotherapy Market: Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Rest of MEA

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

.